{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:10:00Z","timestamp":1772539800201,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejphar.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T06:02:27Z","timestamp":1520488947000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain"],"prefix":"10.1016","volume":"827","author":[{"given":"Kris","family":"Rutten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Tzschentke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.03.008_bib1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1097\/00001756-199510010-00007","article-title":"Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats","volume":"6","author":"Bian","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2018.03.008_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1744-8069-3-37","article-title":"Trafficking of central opioid receptors and descending pain inhibition","volume":"3","author":"Bie","year":"2007","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejphar.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/SPC.0000000000000129","article-title":"Simultaneous targeting of multiple opioid receptor types","volume":"9","author":"Bird","year":"2015","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"10.1016\/j.ejphar.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-2999(98)00597-4","article-title":"Peripheral component in the enhanced antinociceptive effect of systemic U-69,593, a kappa-opioid receptor agonist in mononeuropathic rats","volume":"357","author":"Catheline","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(96)00629-2","article-title":"Further evidence for a peripheral component in the enhanced antinociceptive effect of systemic morphine in mononeuropathic rats: involvement of kappa-, but not delta-opioid receptors","volume":"315","author":"Catheline","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pain.2004.03.037","article-title":"Evidence for an exclusive antinociceptive effect of nociceptin\/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain","volume":"110","author":"Courteix","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(93)90224-D","article-title":"Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain","volume":"53","author":"Desmeules","year":"1993","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.03.008_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-8993(02)02452-6","article-title":"Quantitative autoradiographic mapping of opioid receptors in the brain of delta-opioid receptor gene knockout mice","volume":"945","author":"Goody","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm990517p","article-title":"Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]\u22123-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397)","volume":"42","author":"Kawamoto","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2018.03.008_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2009.03.019","article-title":"Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists","volume":"610","author":"Khroyan","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/sj.bjp.0706346","article-title":"Endogenous opioid mechanisms partially mediate P2X3\/P2X2\/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain","volume":"146","author":"McGaraughty","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-8993(90)90327-8","article-title":"Kappa- and delta-opioid agonists synergize to produce potent analgesia","volume":"509","author":"Miaskowski","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.008_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2008.11.004","article-title":"Role of delta opioid efficacy as a determinant of mu\/delta opioid interactions in rhesus monkeys","volume":"602","author":"Negus","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(00)00520-3","article-title":"In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist","volume":"402","author":"Ozaki","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1476-5381.2012.02075.x","article-title":"Ligand-directed signalling within the opioid receptor family","volume":"167","author":"Pradhan","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-8993(94)91155-X","article-title":"Mu and delta opioid synergy between the periaqueductal gray and the rostro-ventral medulla","volume":"665","author":"Rossi","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2014.08.011","article-title":"Pharmacogenomic study of the role of the nociceptin\/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia","volume":"741","author":"Rutten","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1254\/jphs.13223FP","article-title":"Preventive and alleviative effect of tramadol on neuropathic pain in rats: roles of alpha(2)-adrenoceptors and spinal astrocytes","volume":"124","author":"Sakakiyama","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1111\/bph.12744","article-title":"Functional plasticity of the N\/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists","volume":"171","author":"Schr\u00f6der","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.008_bib21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejpain.2010.05.005","article-title":"Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain","volume":"14","author":"Schr\u00f6der","year":"2010","journal-title":"Eur. J. Pain."},{"key":"10.1016\/j.ejphar.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0006-8993(98)01201-3","article-title":"Quantitative autoradiography of mu-,delta- and kappa1 opioid receptors in kappa-opioid receptor knockout mice","volume":"818","author":"Slowe","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0006-8993(90)91297-T","article-title":"Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids","volume":"530","author":"Sutters","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.008_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","article-title":"(-)-(1R,2R)\u22123-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","volume":"323","author":"Tzschentke","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.03.008_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041909","article-title":"Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation","volume":"7","author":"Varamini","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.03.008_bib26","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1021\/jm300418d","article-title":"Synthesis and biological evaluation of an orally active glycosylated endomorphin-1","volume":"55","author":"Varamini","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2018.03.008_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916667949","article-title":"Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-alpha up-regulation in the sciatic nerve of rats with neuropathic pain: a possible correlation with delta opiod receptors-mediated antiallodinic effect","volume":"12","author":"Vicario","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejphar.2018.03.008_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918301444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918301444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T10:07:36Z","timestamp":1530871656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918301444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":28,"alternative-id":["S0014299918301444"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.008","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}